Leitlinien in Kürze Updates - Pankreas

Zusammenfassung

Mit der 3. Fassung erschien 2024 die überarbeitete und aktualisierte S3-Leitlinie „Exokrines Pankreaskarzinom“. In diesem Artikel geben wir einen Überblick über die wichtigsten Neuerungen in Diagnostik und Therapie.

Abstract

After several revisions and updates since its last publication, the third German S3 guideline “Exocrine pancreatic cancer” was published in 2024. In this article, we provide an overview of the most important innovations in diagnosis and treatment.

Schlüsselwörter

Abdominalchirurgie - Pankreaskarzinom - Pankreaschirurgie - Pankreastumor

Keywords

abdominal surgery - pancreatic carcinoma - pancreatic surgery - pancreatic tumor

Publikationsverlauf

Eingereicht: 10. Dezember 2024

Angenommen: 15. Januar 2025

Artikel online veröffentlicht:
08. April 2025

• Literatur

• 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Exokrines Pankreaskarzinom, Version 3.0, AWMF-Registernummer: 032–010OL. 2024 Zugriff am 03. Februar 2025 unter: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Pankreaskarzinom/Version_3/LL_Pankreaskarzinom_Langversion_3.0.pdf
• 2 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Exokrines Pankreaskarzinom, Version 2.0, AWMF-Registernummer: 032–010OL. 2021 Zugriff am 03. Februar 2025 unter: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Pankreaskarzinom/Version_2/LL_Pankreaskarzinom_Langversion_2.0.pdf
• 3 Lugo A, Peveri G, Bosetti C. et al. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis. Eur J Cancer 2018; 104: 117-126
• 4 Ordonez-Mena JM, Schottker B, Mons U. et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Med 2016; 14: 62
• 5 Xie F, You Y, Huang J. et al. Association between physical activity and digestive-system cancer: An updated systematic review and meta-analysis. J Sport Health Sci 2021; 10: 4-13
• 6 Homma T, Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19–9 and elastase-1 or ultrasonography. Int J Pancreatol 1991; 9: 119-124
• 7 Kim JE, Lee KT, Lee JK. et al. Clinical usefulness of carbohydrate antigen 19–9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19: 182-186
• 8 Isaji S, Mizuno S, Windsor JA. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18: 2-11
• 9 Ta R, O'Connor DB, Sulistijo A. et al. The Role of Staging Laparoscopy in Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Dig Surg 2019; 36: 251-260
• 10 Staerkle RF, Vuille-Dit-Bille RN, Soll C. et al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. Cochrane Database Syst Rev 2021; 1: CD011490
• 11 Wainberg ZA, Melisi D, Macarulla T. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023; 402: 1272-1281
• 12 European Medicines Agency. Onivyde pegylated liposomal (previously Onivyde). 2024 Zugriff am 03. Februar 2025 unter: https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal
• 13 Strickler JH, Satake H, George TJ. et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med 2023; 388: 33-43
• 14 Labori KJ, Bratlie SO, Andersson B. et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2024; 9: 205-217
• 15 Lee J, Dean A, Price T. et al. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial. ESMO Gastrointestinal Oncology 2023; 1: 3-8
• 16 Enzler T, Nguyen A, Misleh J. et al. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. Eur J Cancer 2024; 201: 113950